Aim: To study the efficacy of the Medtronic MiniMed 640G insulin pump (CSII with Suspend before low (Predictive Low-Glucose Management [PLGM]) on glycemic control in patients with diabetes mellitus type 1 (DMT1) at baseline, after the first trimester and after 18 months’ use.

Patients/Methods: Thirteen patients with DMT1 participated who were on PLGM system (Minimed 640G system-Medtronic), 8 females, age 45.8±12.5 years, DM duration 28.1±8.5 years and PLGM duration 17.5±7.4 months. HbA1c, anthropometric measurements and medical history were recorded at baseline, after 3 months and after 18 months’ use of the PLGM system. The continuous glucose measurements (CGM) data of the last two weeks of each interval were downloaded using the software Carelink Pro and Personal.

Results: The glycemic control after using PLGM system was significantly better compared with baseline at 3 and 18 months’ use (HbA1c 7.2±0.7% vs. 6.6±0.5 vs. 6.7±0.5, p=0.006). There was an improvement at first trimester compared with baseline (HbA1c 6.6±0.5 vs. 7.2±0.7, p=0.027) and at 18 months’ use compared with baseline (HbA1c 6.7±0.5 vs. 7.2±0.7, p=0.046). There was no difference in glycemic control between 3 and 18 months’ use. There was no difference of time duration < 3.9 mmol/l (min/day), hypoglycemic episodes and AUC < 3.9 mmol/l compared with baseline at 3 and 18 months’ use. There was a reduction of the time duration > 9.9 mmol/l (min/day) between baseline and after 18 months’ use (3281.3±2175.9 vs. 1891.6±555.7, p=0.037). Hyperglycemic events were reduced significantly after 18 months compared to baseline (median 28.5, interquartile range (IQR) 14 vs. median 39.5, IQR 19, p=0.045).

Conclusion: Patients with DMT1 using CSII with PLGM system for 18 months improved their glycemic control due to the reduction of hyperglycemic fluctuation. Glycemic control improved after 3 months and that improvement persisted for 18 months of follow-up.

Disclosure

T. Didandelos: None. P. Giannoulaki: None. E. Karlafti: None. E. Kotzakioulafi: None. Z. Kontoninas: None. K. Tziomalos: None. A.I. Hatzitolios: None.

© 2018 by the American Diabetes Association.
2018
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.